Disease Burden and Long-Term Risk of Persistent Very Poorly Controlled Asthma: TENOR II {#sec1aa}
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**Haselkorn et al**  2243

***What is already known about this topic?*** The Epidemiology and Natural history of Asthma: Outcomes and Treatment Regimens I demonstrated that patients with severe/difficult-to-treat asthma have a substantial disease burden and unmet medical need. More than a decade later, The Epidemiology and Natural history of Asthma: Outcomes and Treatment Regimens II provides a longitudinal assessment of these patients receiving standard of care.

***What does this article add to our knowledge?*** Nearly 50% of patients had persistent very poorly controlled asthma. Risk factors predictive of persistent very poorly controlled asthma were black versus white race/ethnicity, allergic trigger count (4 vs 0), systemic corticosteroid use, and reduced percent predicted postbronchodilator FEV~1~.

***How does this study impact current management guidelines?*** Despite standard of care, persistent very poorly controlled asthma remains a severe disease characterized by excess comorbidities, numerous allergic triggers, poor lung function, and high health care utilization, emphasizing need for more intensive management, including assessment and improvement of modifiable risk factors.

Paradoxical Vocal Fold Motion in Difficult Asthma Is Associated with Dysfunctional Breathing and Preserved Lung Function {#sec1}
========================================================================================================================

**Lee et al**  2256

***What is already known about this topic?*** Patients with "difficult-to-treat" asthma may also have comorbidities, such as vocal cord dysfunction, which are associated with worse asthma outcomes, such as exacerbation risk, high symptom burden, and poorer quality of life.

***What does this article add to our knowledge?*** Clinical features associated with vocal cord dysfunction amongst patients with difficult asthma include dysfunctional breathing and preserved lung function.

***How does this study impact current management guidelines?*** Identifying and treating dysfunctional breathing alongside vocal cord dysfunction should be included in management guidelines for patients with difficult asthma and is likely to be essential to improve patient outcomes.

Development of the Asthma Impairment and Risk Questionnaire (AIRQ): A Composite Control Measure {#sec2}
===============================================================================================

**Murphy et al**  2263

***What is already known about this topic?*** Despite the importance of using asthma control tools to measure symptom control and risk for future exacerbations in patients with uncontrolled asthma, most tools only assess impairment.

***What does this article add to our knowledge?*** This article describes the validation of a novel composite asthma control measure, the Asthma Impairment and Risk Questionnaire (AIRQ), which includes both impairment and risk domains of control.

***How does this study impact current management guidelines?*** The AIRQ may complement current guidelines by facilitating the identification of asthma morbidity that currently goes unrecognized in clinical practice.

Latent Class Analysis of School-Age Children at Risk for Asthma Exacerbation {#sec3}
============================================================================

**Grunwell et al**  2275

***What is already known about this topic?*** Children at risk for asthma exacerbations are a heterogeneous group, with clinical features and pathophysiologic mechanisms that may differ from those that drive asthma severity. There are few studies of children at risk for exacerbation.

***What does this article add to our knowledge?*** Latent class analysis identified 4 groups that differed in demographic features, sensitization/type 2 markers, lung function variables, and future exacerbation occurrence. Exacerbations were most prevalent in latent classes with multiple sensitization and airflow limitation.

***How does this study impact current management guidelines?*** Multiple sensitization, in addition to previous exacerbations and lung function, may be a useful predictor of future exacerbations. However, exacerbations were common in each latent class and highlight the heterogeneity of asthma in school-age children.

Events in Normal Skin Promote Early-Life Atopic Dermatitis---The MPAACH Cohort {#sec4}
==============================================================================

**Biagini Myers et al**  2285

***What is already known about this topic?*** Nonlesional skin in atopic dermatitis (AD) is abnormal, but the pathobiology of lesional and nonlesional skin and the definition of endotypes are poorly understood.

***What does this article add to our knowledge?*** This study reveals that events in the nonlesional, not the lesional, skin promote the subsequent development of AD severity and cosensitization, which is a key risk factor for allergic comorbidities.

***How does this study impact current management guidelines?*** Our study suggests that management of pediatric AD should include treatment of both lesional and nonlesional skin, because subclinical inflammation in normal-appearing areas may predispose to allergic comorbidities and more severe disease.

Direct Challenges to Penicillin-Based Antibiotics in the Inpatient Setting {#sec5}
==========================================================================

**Ramsey et al**  2294

***What is already known about this topic?*** Direct challenge to penicillin has been shown in multiple studies to be a safe and effective delabeling strategy in penicillin-allergic patients with low-risk reaction histories.

***What does this article add to our knowledge?*** This article is among the first to demonstrate the safety and feasibility of direct challenge for adult inpatients reporting a low-risk penicillin allergy history.

***How does this study impact current management guidelines?*** This study expands the inpatient setting data on the safety of direct challenge in adult inpatients with a low-risk reaction history, allowing for more patients to be delabeled without more costly and resource-intensive penicillin skin testing.

Prehospital Treatment and Emergency Department Outcomes in Young Children with Food Allergy {#sec6}
===========================================================================================

**Ko et al**  2302

***What is already known about this topic?*** Previous studies have demonstrated potential differences between infants and older children in food allergy presentation. Data examining outcomes after prehospital treatment of food allergy reactions and anaphylaxis have offered differing conclusions.

***What does this article add to our knowledge?*** This study shows that infants presenting to the emergency department (ED) with food allergy reactions have different characteristics than older children. Prehospital epinephrine was associated with a higher likelihood of hospital observation. Epinephrine treatment overall was underused.

***How does this study impact current management guidelines?*** Our data shows that epinephrine is underutilized as an ED treatment for food-induced anaphylaxis in young children. More education is needed to help health care providers recognize and treat anaphylaxis in the very young.

Health and Economic Outcomes of Home Maintenance Allergen Immunotherapy in Select Patients with High Health Literacy during the COVID-19 Pandemic: A Cost-Effectiveness Analysis During Exceptional Times {#sec7}
=========================================================================================================================================================================================================

**Shaker et al**  2310

***What is already known on this topic:*** Allergy/immunology clinical practices are not immune to natural disasters or global pandemics, which may force service reduction or abrupt changes in practice.

***What does this article add to our knowledge:*** Home allergen immunotherapy can be cost-effective in highly selected patients under pandemic shelter-in-place conditions provided home systemic reactions to immunotherapy rates remain stable; however, careful patient selection is critical.

***How does this study impact current management guidelines:*** This cost-effectiveness analysis demonstrates potential feasibility of allergen immunotherapy for appropriately screened patients. This may help inform decision making regarding how to provide this valuable allergy service in a current or future natural disaster or pandemic.

Efficacy and Safety of Ragweed SLIT-Tablet in Children with Allergic Rhinoconjunctivitis in a Randomized, Placebo-Controlled Trial {#sec8}
==================================================================================================================================

**Nolte et al**  2322

***What is already known about this topic?*** Ragweed allergy is common in children.

***What does this article add to our knowledge?*** The results of this large, international, double-blind, placebo-controlled trial indicate that ragweed sublingual immunotherapy tablet has a significant clinical benefit on allergic rhinitis with or without conjunctivitis outcomes in children with ragweed pollen--induced allergy and is well tolerated.

***How does this study impact current management guidelines?*** Ragweed sublingual immunotherapy tablet is effective and well tolerated and may provide a convenient treatment option for children with ragweed pollen--induced allergic rhinitis with or without conjunctivitis.

Preserved Cellular Immunity Upon Influenza Vaccination in Most Patients with Common Variable Immunodeficiency {#sec9}
=============================================================================================================

**Friedmann et al**  2332

***What is already known about this topic?*** Annual influenza vaccination is recommended for patients with common variable immunodeficiency although reports about B- and T-cell responses are sparse and contradictory.

***What does this article add to our knowledge?*** Antigen-specific T-cell responses are heterogeneous according to the assay used but present in most patients with CVID.

***How does this study impact current management guidelines?*** In view of lacking data on clinical end points of T-cell immunity in influenza infection, influenza vaccination of all patients with common variable immunodeficiency is reasonable.

Development and Preliminary Validation of a New Patient-Reported Outcome Measure for Chronic Rhinosinusitis (CRS-PRO) {#sec10}
=====================================================================================================================

**Ghadersohi et al**  2341

***What is already known about this topic?*** Patient-reported outcome (PRO) measures quantify health-related impairment and can serve as endpoints for clinical trials in chronic rhinosinusitis (CRS). Few PRO instruments for CRS are developed with documented input from patients with current CRS definitions and are not accepted by the Food and Drug administration (FDA) as an endpoint for clinical trials.

***What does this article add to our knowledge?*** The 12-item CRS-PRO is a new disease-specific PRO measure of CRS. It was developed using extensive input from patients meeting current definitions of CRS, is more concise than current PRO measures (eg, Sinonasal Outcome Test-22), and possesses equivalent reliability and validity.

***How does this study impact current management guidelines?*** The validated CRS-PRO was developed in concordance with current FDA guidelines on PRO measures. This study, along with developmental documentation, can be used to support acceptance of the CRS-PRO as an endpoint for clinical trials.

Responsiveness and Convergent Validity of a New Patient-Reported Outcome Measure for Chronic Rhinosinusitis (CRS-PRO) {#sec11}
=====================================================================================================================

**Ghadersohi et al**  2351

***What is already known about this topic?*** The 22-item Sino-Nasal Outcome Test is the best currently available patient-reported outcome measure for chronic rhinosinusitis (CRS). However, its development process may preclude Food and Drug Administration acceptance as an end point for use in clinical trials.

***What does this article add to our knowledge?*** The 12-item CRS-PRO is a responsive and valid disease-specific patient-reported outcome measure of CRS. It is more concise than current patient-reported outcome measures (ie, 22-item Sino-Nasal Outcome Test) and was developed using extensive input from patients with CRS, including patients with CRS with nasal polyps.

***How does this study impact current management guidelines?*** The validated CRS-PRO was developed with extensive documented input from patients with CRS. It was developed in concordance with Food and Drug Administration guidelines on patient-reported outcome measures acceptable for use as end points in clinical trials.

Optimizing Value in the Evaluation of Chronic Spontaneous Urticaria: A Cost-Effectiveness Analysis {#sec12}
==================================================================================================

**Shaker et al**  2360

***What is already known about this topic?*** The Choosing Wisely campaign recommends not routinely performing laboratory testing in patients with chronic spontaneous urticaria with otherwise normal histories and physical evaluations. The cost-effectiveness of such testing has not been formally evaluated.

***What does this article add to our knowledge?*** Routine laboratory screening in patients with chronic urticaria with normal histories and examinations is not cost-effective, even if therapy costs are reduced by identifying a secondary cause. On a population level screening costs could reach \$941,750,741 to \$1,833,501,483.

***How does this study impact current management guidelines?*** Routine laboratory screening in chronic urticaria is a low-value medical practice that is not cost-effective, given laboratory tests rarely improve outcomes.

Omalizumab Re-Treatment and Step-Up in Patients with Chronic Spontaneous Urticaria: OPTIMA Trial {#sec13}
================================================================================================

**Sussman et al**  2372

***What is already known about this topic?*** Phase 3 trials have shown that omalizumab is effective at both doses (150 mg/300 mg) in patients with chronic spontaneous urticaria, with the 300 mg dose showing greater clinical benefit.

***What does this article add to our knowledge?*** After initial omalizumab treatment, symptom control after relapse and re-treatment is achieved in almost all patients. Initial benefit is greater with a 300 mg dose than a 150 mg dose; step-up to 300 mg improves symptom control.

***How does this study impact current management guidelines?*** Step-up therapy to 300 mg helps a greater proportion of patients achieve symptom control, and re-treatment with omalizumab is as effective as initial therapy.

Clinical Characteristics and Safety of Plasma-Derived C1-Inhibitor Therapy in Children and Adolescents with Hereditary Angioedema---A Long-Term Survey {#sec14}
======================================================================================================================================================

**Farkas et al**  2379

***What is already known about this topic?*** Limited information is available on the characteristics of clinical symptoms and on the long-term safety of plasma-derived C1-inhibitor in pediatric patients with hereditary angioedema with C1-inhibitor deficiency (C1-INH-HAE) of different ages and genders.

***What does this article add to our knowledge?*** According to our long-term, real-life observation with regular, annual follow-up of patients with C1-INH-HAE, plasma-derived C1-INH is safe for acute treatment and for short-term or intermittent prophylaxis in pediatric age groups.

***How does this study impact current management guidelines?*** The age and gender of pediatric patients influence the clinical manifestations of the disease. The complex therapeutic strategy is mainly based on plasma-derived C1-INH as a first-line therapy.
